Work

Spacing out dual checkpoint inhibition improves antigen-specific T cell manufacture

Year: 2022

Type: article

Abstract: The adoptive transfer of antigen-specific T cells is a promising therapy for treating infection, cancer, and autoimmunity. To generate large numbers of antigen-specific T cells, however, most protocols rely on in vitro culture with cytokines and repeated antigenic stimulation. This leads to terminal T cell effector differentiation and exhaustion, limiting the utility of expanded T cells.1,2,3 In this issue of Molecular Therapy – Methods and Clinical Development, Lak et al. demonstrate that blocking both programmed death-ligand 1 (PD-L1) and T cell immunoglobulin and mucin-containing protein 3 (TIM-3) during the generation of antigen-specific CD8+ T cells led to improved T cell expansion without inducing T cell dysfunction, but only when blockade was induced with specific timing.

Source: Molecular Therapy — Methods & Clinical Development

DOI: 10.1016/j.omtm.2022.11.007

Authors: Hanmin Wang, Leo D. Wang

Institutions: City Of Hope National Medical Center, Beckman Research Institute

Language: English

Topic: T-cell and B-cell Immunology

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900